Somewhat Positive Press Coverage Somewhat Unlikely to Impact Leap Therapeutics (LPTX) Share Price

News coverage about Leap Therapeutics (NASDAQ:LPTX) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Leap Therapeutics earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.6139398693636 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Leap Therapeutics traded up $0.65, hitting $7.31, during trading hours on Friday, according to Marketbeat Ratings. The company’s stock had a trading volume of 77,492 shares, compared to its average volume of 35,200. Leap Therapeutics has a 12 month low of $4.90 and a 12 month high of $10.25.

Leap Therapeutics (NASDAQ:LPTX) last posted its earnings results on Wednesday, August 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.01). analysts anticipate that Leap Therapeutics will post -2.23 EPS for the current fiscal year.

Several research analysts have recently commented on LPTX shares. Zacks Investment Research upgraded Leap Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a report on Tuesday, July 17th. ValuEngine upgraded Leap Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Further Reading: Outstanding Shares

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply